The Journal of Practical Medicine ›› 2023, Vol. 39 ›› Issue (16): 2112-2115.doi: 10.3969/j.issn.1006-5725.2023.16.017

• Drugs and Clinic Practice • Previous Articles     Next Articles

Efficacy and safety of chemotherapy plus immunotherapy and recombinant human endostatin in treating advanced non-small cell lung cancer

Xianlan ZHANG1,Yufei ZHU2,Yunyun ZENG1,Zhihao HUANG1,Wenchang CEN1,Shan. SU1()   

  1. *.Department of Oncology,Guangzhou Chest Hospital,Guangzhou 510095,China
  • Received:2023-04-27 Online:2023-08-25 Published:2023-09-26
  • Contact: Shan. SU E-mail:susan705@126.com

Abstract:

Objective To investigate the efficacy and safety of chemotherapy plus immunotherapy and recombinant human endostatin in treating patients with advanced non-small cell lung cancer (NSCLC). Methods We retrospectively reviewed and analyzed the medical records of 24 patients with advanced NSCLC treated with chemotherapy plus immunotherapy and recombinant human endostatin in Guangzhou Chest Hospital from June 2020 to December 2022. We focused on analyses of progression-free survival (PFS) and objective response rate (ORR) as well as disease control rate (DCR) and adverse events (AEs). Results At 19.2 months′ median follow-up, the median PFS (mPFS) was 11 months (95%CI:8.722 ~ 13.278). Among them, 11 patients received first-line treatment with an mPFS of 11 months (95%CI:9.782 ~ 12.218). The 6-month and 12-month PFS rates were 82.4% and 52.9%, respectively. The first-line treatment elicited an ORR of 58.8%, and a DCR of 94.1%. Among the 17 cases, 2 came out with grade 3 - 4 AEs, taking up 11.8%, among which hematotoxicity was the most common, and 8 with grade 1 - 2 AEs, taking up 47.1%, among which hematotoxicity accounted for 17.6%, pruritus for 17.6% and hepatic toxicity for 5.9%. Conclusion Chemotherapy plus immunotherapy and endostatin promises good efficacy and safety in treating patients with advanced NSCLC.

Key words: lung cancer, non-small cell, chemotherapy, immunotherapy, recombinant human endostatin

CLC Number: